SURMOUNT-5
The randomized head-to-head trial (published NEJM, 2025) comparing tirzepatide and semaglutide at maximum tolerated doses: roughly 20% versus 14% average body-weight reduction at 72 weeks — about 47% greater relative loss for tirzepatide. The single most decision-relevant efficacy datapoint in this category, and a result about the approved products, not compounded copies.
Released · Last reviewed · how we verify
Seen against the November 20, 2026 re-read: compounded tirzepatide runs from $85.58 to $399 and semaglutide from $75.58 to $299 per billing cycle, all-in, among programs that print a comparable price, so terms like this one decide whether the advertised number matches the bill. Every definition in this glossary links back to the places in the database and the methodology where the concept does its work.
That ~20% vs ~14% result is why tirzepatide carries a premium in every lane of this index. Related figures live on the pages this term links to, and every one of them regenerates from the same dataset this definition does.
See the term in action across the price database and the methodology.